Identity
- Security key
- 19310
- Ticker
- NRSN
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-12-09
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- NRSN
Detail
Enriched 2026-08-14 20:47
- Market cap
- $17,700,970.13
- Shares outstanding (class)
- 37,766,098
- Shares outstanding (weighted)
- 37,766,098
- SIC
- —
- Employees
- 16
- Location
- —
- Homepage
- https://www.neurosense-tx.com
- Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.